VIA
CPRX

Virtus Investment Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Virtus Investment Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,713
Closed -$432K – 521
2024
Q4 		$432K Hold
20,713
– – 0.34% 104
2024
Q3 		$412K Buy
20,713
+14,000
+209% +$260K 0.32% 100
2024
Q2 		$104K Hold
6,713
– – 0.09% 237
2024
Q1 		$107K Hold
6,713
– – 0.08% 241
2023
Q4 		$113K Hold
6,713
– – 0.08% 233
2023
Q3 		$78.5K Hold
6,713
– – 0.05% 233
2023
Q2 		$90.2K Hold
6,713
– – 0.06% 247
2023
Q1 		$111K Buy
+6,713
New +$111K 0.08% 240

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Virtus Investment Advisers's CPRX Position: Q1 2025 in Review

Virtus Investment Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 20,713 shares — an estimated $432K sold.

Virtus Investment Advisers first reported a position in CPRX in Q1 2023 and held it in 8 quarters. The position peaked at $432K in Q4 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Virtus Investment Advisers reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 20,713 Catalyst Pharmaceutical shares in Q1 2025, an estimated $432K.
  • Virtus Investment Advisers first reported a position in Catalyst Pharmaceutical in Q1 2023 and held it in 8 quarters.
  • Virtus Investment Advisers's Catalyst Pharmaceutical position peaked at $432K in Q4 2024.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Virtus Investment Advisers's 13F filing for Q1 2025, filed 15 May 2025.